Literature DB >> 26069881

Substance use disorders and avoidable mortality after prison.

Sarah E Wakeman1, Josiah D Rich2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26069881      PMCID: PMC4461078          DOI: 10.1016/S2215-0366(15)00125-X

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


× No keyword cloud information.
Worldwide, more than 30 million people spend time in prison every year.[1] The USA incarcerates 25% of these people and one in 31 Americans is currently under correctional control, either in jail, prison, or on probation or parole.[2] Most prisoners will eventually be released, and the 2 weeks after release have been shown to be associated with a substantial increase in mortality, especially from overdose.[3] Substance use disorders are highly prevalent among incarcerated populations, with more than half of prisoners in some countries being imprisoned for drug-related convictions.[4] In the USA, 85% of people in prisons or jails are substance involved, with 1·5 million individuals meeting DSM criteria for a substance use disorder and an additional 458 000 either with a history of substance use, under the influence at the time of arrest, or convicted of a crime committed to obtain money to buy drugs.[5] Addiction is a treatable disease and decades of scientific evidence support the efficacy of treatment to improve clinical outcomes, save lives, and reduce societal costs. Treatment for opioid use disorder during incarceration with agonists such as buprenorphine or methadone has been shown to reduce recidivism, improve treatment retention, reduce illicit drug use, and decrease criminal activity.[6,7] Buprenorphine has also been shown to decrease the risk of overdose death by more than 50%.[8] However, despite the overwhelming evidence, treatment remains variable between correctional facilities and few prisoners receive these life-saving drugs.[9] In The Lancet Psychiatry, Zheng Chang and colleagues[10] examined mortality in all people released from prison in Sweden between Jan 1, 2000, and Dec 31, 2009. In this sample of 47 326 individuals and 238 457 person-years of follow-up, the researchers reported that substance use (both alcohol and illicit drug use) was related to a substantial proportion of post-release mortality, even when controlling for other factors using imprisoned siblings as controls. The association between mental illness and post-release mortality disappeared when substance use was controlled for. This well designed study of an entire country offers important and concerning new data on the high risk of death for individuals with substance use disorder who are incarcerated. The results of the study also showed that the period of risk of increased mortality after release from prison is much longer— months to years—than the few weeks previously reported,[3] an important finding that is probably true in most places. These findings are even more alarming when considering the magnitude of risk for a country such as the USA, which has a much higher incarceration rate and far more drug-related convictions than does Sweden. Access to effective treatments for addiction, particularly pharmacotherapy, is the single greatest intervention that can reduce the death toll from overdose.[11] The withholding of evidence-based treatment for prisoners is arguably unethical and certainly unwise. In the USA, correctional facilities are mandated by the Supreme Court to provide medical care that meets the community standard.[12] And yet, within state prisons people with drug use disorders largely go without care: of these people, only 0·8% receive detoxification services, 0·3% receive maintenance pharmacotherapy, 6·5% receive counselling by a professional, and 9·5% receive treatment in a residential facility.[13] Even those on treatment in the community are systematically forced off when incarcerated, with detrimental consequences.[14] The absence of care in this deeply affected population translates into high costs to society and the communities that these individuals return to. As the Article shows, these costs also translate into avoidable deaths from a treatable illness.
  8 in total

1.  Attitudes and practices regarding the use of methadone in US state and federal prisons.

Authors:  Josiah D Rich; Amy E Boutwell; David C Shield; R Garrett Key; Michelle McKenzie; Jennifer G Clarke; Peter D Friedmann
Journal:  J Urban Health       Date:  2005-05-25       Impact factor: 3.671

2.  Release from prison--a high risk of death for former inmates.

Authors:  Ingrid A Binswanger; Marc F Stern; Richard A Deyo; Patrick J Heagerty; Allen Cheadle; Joann G Elmore; Thomas D Koepsell
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.

Authors:  V Tomasino; A J Swanson; J Nolan; H I Shuman
Journal:  Mt Sinai J Med       Date:  2001-01

4.  Physicians in US Prisons in the Era of Mass Incarceration.

Authors:  Scott A Allen; Sarah E Wakeman; Robert L Cohen; Josiah D Rich
Journal:  Int J Prison Health       Date:  2010-12-01

5.  Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.

Authors:  Josiah D Rich; Michelle McKenzie; Sarah Larney; John B Wong; Liem Tran; Jennifer Clarke; Amanda Noska; Manasa Reddy; Nickolas Zaller
Journal:  Lancet       Date:  2015-05-28       Impact factor: 79.321

6.  A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady
Journal:  Addiction       Date:  2008-08       Impact factor: 6.526

7.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

8.  Substance use disorders, psychiatric disorders, and mortality after release from prison: a nationwide longitudinal cohort study.

Authors:  Zheng Chang; Paul Lichtenstein; Henrik Larsson; Seena Fazel
Journal:  Lancet Psychiatry       Date:  2015-04-28       Impact factor: 27.083

  8 in total
  1 in total

Review 1.  Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

Authors:  Cayley Russell; Shannon Lange; Fiona Kouyoumdjian; Amanda Butler; Farihah Ali
Journal:  Harm Reduct J       Date:  2022-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.